PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma | Zendy

Michael R. Migden | Zendy; Danny Rischin | Zendy; Chrysalyne D. Schmults | Zendy; Alexander Guminski | Zendy; Axel Hauschild | Zendy; Karl D. Lewis | Zendy; Christine H. Chung | Zendy; Leonel F. HernandezAya | Zendy; Annette M. Lim | Zendy; Anne Lynn S. Chang | Zendy; Guilherme Rabinowits | Zendy; Alesha Thai | Zendy; Lara Dunn | Zendy; Brett Hughes | Zendy; Nikhil I. Khushalani | Zendy; Badri Modi | Zendy; Dirk Schadendorf | Zendy; Bo Gao | Zendy; Frank Seebach | Zendy; Siyu Li | Zendy; Jingjin Li | Zendy; Melissa Mathias | Zendy; Jocelyn Booth | Zendy; Kosalai Kal Mohan | Zendy; Elizabeth Stankevich | Zendy; Hani M. Babiker | Zendy; Irene Braña | Zendy; Marta Gil-Martín | Zendy; Jade Homsi | Zendy; Melissa L. Johnson | Zendy; Víctor Moreno | Zendy; Jiaxin Niu | Zendy; Taofeek K. Owonikoko | Zendy; Kyriakos P. Papadopoulos | Zendy; George D. Yancopoulos | Zendy; Israel Lowy | Zendy; Matthew G. Fury | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Author(s) -

Michael R. Migden,

Danny Rischin,

Chrysalyne D. Schmults,

Alexander Guminski,

Axel Hauschild,

Karl D. Lewis,

Christine H. Chung,

Leonel F. HernandezAya,

Annette M. Lim,

Anne Lynn S. Chang,

Guilherme Rabinowits,

Alesha Thai,

Lara Dunn,

Brett Hughes,

Nikhil I. Khushalani,

Badri Modi,

Dirk Schadendorf,

Bo Gao,

Frank Seebach,

Siyu Li,

Jingjin Li,

Melissa Mathias,

Jocelyn Booth,

Kosalai Kal Mohan,

Elizabeth Stankevich,

Hani M. Babiker,

Irene Braña,

Marta Gil-Martín,

Jade Homsi,

Melissa L. Johnson,

Víctor Moreno,

Jiaxin Niu,

Taofeek K. Owonikoko,

Kyriakos P. Papadopoulos,

George D. Yancopoulos,

Israel Lowy,

Matthew G. Fury

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1805131

Subject(s) - medicine , cohort , oncology , immunosuppression

No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high and the disease risk is strongly associated with immunosuppression. In the dose-escalation portion of the phase 1 study of cemiplimab, a deep and durable response was observed in a patient with metastatic cutaneous squamous-cell carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research